Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Marco Mojoli
Based on 4 articles published since 2009
(Why 4 articles?)
||||

Between 2009 and 2019, Marco Mojoli wrote the following 4 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Guideline [SICI-GISE Position paper: Use of Absorb BVS in clinical practice]. 2016

Tarantini, Giuseppe / Saia, Francesco / Capranzano, Piera / Cortese, Bernardo / Mojoli, Marco / Boccuzzi, Giacomo / Cuculo, Andrea / Geraci, Salvatore / Mattesini, Alessio / Oreglia, Jacopo / Summaria, Francesco / Testa, Luca / Berti, Sergio / Esposito, Giovanni / La Manna, Alessio / Limbruno, Ugo / Marchese, Alfredo / Mauro, Ciro / Tarantino, Fabio / Salvi, Alessandro / Santoro, Gennaro / Varbella, Ferdinando / Violini, Roberto / Musumeci, Giuseppe. ·Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari, Policlinico Universitario, Padova. · Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna. · Dipartimento Cardiovascolare, Ospedale Ferrarotto, Università degli Studi, Catania. · Cardiologia Interventistica, A.O. Fatebenefratelli, Milano. · Cardiologia Interventistica, Azienda Sanitaria Locale Torino 2, Torino. · Dipartimento di Cardiologia, A.O. Ospedali Riuniti, Foggia. · Cardiologia Interventistica, Ospedale S. Giovanni di Dio, Agrigento. · Cardiologia Interventistica, Ospedale Moriggia Pelascini, Gravedona (CO). · Emodinamica, ASST Grande Ospedale Metropolitano Niguarda, Milano. · Dipartimento di Cardiologia, Policlinico Casilino, Roma. · Dipartimento di Cardiologia, IRCCS Policlinico S. Donato, S. Donato Milanese (MI). · U.O. Cardiologia Diagnostica ed Interventistica, Fondazione Toscana "Gabriele Monasterio", Ospedale del Cuore, Massa. · Dipartimento di Scienze Biomediche Avanzate, Università degli Studi "Federico II", Napoli. · U.O.C. Cardiologia, Azienda USL Toscana Sudest, Grosseto. · U.O.C. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari. · Dipartimento Cardiovascolare, Ospedale Cardarelli, Napoli. · Laboratorio di Emodinamica, U.O. Cardiologia, Ospedale G.B. Morgagni-L. Pierantoni, Forlì. · Dipartimento Cardiovascolare, Ospedali Riuniti, Università degli Studi, Trieste. · Cardiologia Interventistica, AOU Careggi, Firenze. · Dipartimento di Cardiologia, Ospedale degli Infermi, Rivoli (TO). · Cardiologia Interventistica, Ospedale S. Camillo-Forlanini, Roma. · Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo. ·G Ital Cardiol (Rome) · Pubmed #27729667.

ABSTRACT: Drug-eluting stents (DES) are the current gold standard for percutaneous treatment of coronary artery disease. However, DES are associated with a non-negligible risk of long-term adverse events related to persistence of foreign material in the coronary artery wall. In addition, DES implantation causes permanent caging of the native vessel, thus impairing normal vasomotricity and the possibility of using non-invasive coronary imaging or preforming subsequent bypass surgery. On the contrary, coronary bioresorbable stents (BRS) may provide temporary mechanical support to coronary wall without compromising the subsequent recovery of normal vascular physiology, and have the potential to prevent late adverse events related to permanent elements. Several types of BRS have been introduced into clinical practice in Europe or are being tested. However, most of available clinical data relate to a single BRS, the Absorb bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA). Despite encouraging clinical results, no societal guidelines are available on the use of BRS in clinical practice.A panel of Italian expert cardiologists assembled under the auspices of the Italian Society of Interventional Cardiology (SICI-GISE) for comprehensive discussion and consensus development, with the aim to provide recommendations on the use of bioresorbable stents in terms of clinical indications, procedural aspects, post-percutaneous coronary angioplasty pharmacologic treatment and follow-up. Based on current evidence and BRS availability in Italian cath-labs, the panel decided unanimously to provide specific recommendations for the Absorb BVS device. These recommendations do not necessarily extend to other BRS, unless specified, although significant overlap may exist with Absorb BVS, particularly in terms of clinical rationale.

2 Review Survival After Varying Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: A Pairwise and Network Meta-Analysis. 2016

Tarantini, Giuseppe / D'Amico, Gianpiero / Brener, Sorin J / Tellaroli, Paola / Basile, Marco / Schiavo, Alessandro / Mojoli, Marco / Fraccaro, Chiara / Marchese, Alfredo / Musumeci, Giuseppe / Stone, Gregg W. ·Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. Electronic address: giuseppe.tarantini.1@gmail.com. · Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Department of Medicine, Cardiac Catheterization Laboratory, New York Methodist Hospital, New York, New York. · Epidemiology and Public Health Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Anthea Hospital, GVM Care & Research, Cardiology Unit, Bari, Italy. · Papa Giovanni XXIII Hospital, Bergamo, Italy. · Columbia University Medical Center, New York Presbyterian Hospital, and the Cardiovascular Research Foundation, New York, New York. ·JACC Cardiovasc Interv · Pubmed #27609250.

ABSTRACT: OBJECTIVES: The authors conducted a systematic pairwise and network meta-analysis to assess optimal treatment strategies in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MV-CAD) undergoing primary percutaneous coronary intervention (PCI). BACKGROUND: Patients with STEMI and MV-CAD have a worse prognosis than those with single-vessel CAD. The optimal revascularization strategy for these patients is uncertain. METHODS: Studies of revascularization strategies for MV-CAD in STEMI patients undergoing primary PCI published between 2001 and 2015 were identified using an electronic search. Pairwise and network meta-analyses were performed for 3 PCI strategies in prospective and retrospective studies: 1) infarct-related artery (IRA)-only PCI; 2) single procedure MV-PCI; and 3) staged MV-PCI. Information on study design, inclusion and exclusion criteria, and clinical outcomes was extracted. The outcomes of interest were short-term and long-term mortality. RESULTS: Thirty-two studies (13 prospective and 19 retrospective) with 54,148 patients (IRA-only PCI [n = 42,112], single procedure MV-PCI [n = 8,138], and staged MV-PCI [n = 3,898]) were included in the analysis. Pairwise meta-analyses showed that staged MV-PCI was associated with lower short-term and long-term mortality compared with both IRA-only PCI and single stage MV-PCI, whereas IRA-only PCI was associated with lower mortality compared with single stage MV-PCI. Staged MV-PCI was also associated consistently with improved survival in network analyses. CONCLUSIONS: The present systematic review and meta-analysis supports the hypothesis that in patients with MV-CAD presenting with STEMI undergoing primary PCI, a staged multivessel revascularization strategy may improve early and late survival.

3 Clinical Trial "Full-plastic jacket" with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413). 2018

Tarantini, Giuseppe / Masiero, Giulia / Fovino, Luca Nai / Mojoli, Marco / Varricchio, Attilio / Loi, Bruno / Gistri, Roberto / Misuraca, Leonardo / Gabrielli, Gabriele / Cortese, Bernardo / Pisano, Francesco / Moretti, Luciano / Tumminello, Gabriele / Olivari, Zoran / Mazzarotto, Pietro / Colombo, Alessandro / Calabrò, Paolo / Nicolino, Annamaria / Tellaroli, Paola / Corrado, Donatella / Durante, Alessandro / Steffenino, Giuseppe / Anonymous2021030. ·Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. Electronic address: giuseppe.tarantini.1@unipd.it. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Interventional Cardiology, A.O. Monaldi, Naples, Italy. · Cardiology Division, A.O. Brotzu, Cagliari, Italy. · Interventional Cardiology, S. Andrea Hospital, La Spezia, Italy. · U.O. Cardiologia-Emodinamica, Ospedale della Misericordia, Grosseto, Italy. · Interventional Cardiology Unit, Azienda Ospedali Riuniti, Ancona, Italy. · Interventional Cardiology, A.O. Fatebenefratelli, Milan, Italy. · Interventional Cardiology, Parini Regional Hospital, Aosta, Italy. · Cardiology Division, Mazzoni Hospital, Ascoli Piceno, Italy. · Cardinal Massaia Hospital, Asti, Italy. · Cardiology Division, Ca' Foncello Hospital, Treviso, Italy. · Interventional Cardiology, Ospedale Maggiore, Lodi, Italy. · Interventional Cardiology Unit, Luigi Sacco Hospital, Milano, Italy. · Division of Cardiology, Department of Cardio-Thoracic Sciences, Second University of Naples, Naples, Italy. · Interventional Cardiology Unit, Santa Corona General Ospital, Pietra Ligure, Italy. · Biostatistics, Epidemiology and Public Health Unit of Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · "Mario Negri" Research Institute, Milano, Italy. · Cardiology Division, Valduce Hospital, Como, Italy. · USD Emodinamica, A.S.O. S.Croce e Carle, Cuneo, Italy. ·Int J Cardiol · Pubmed #29887475.

ABSTRACT: OBJECTIVES: The objective of this study was to investigate mid-term clinical outcomes of patients treated with 'full-plastic jacket' (FPJ) everolimus-eluting Absorb bioresorbable vascular scaffold (BRS) implantation. BACKGROUND: FPJ with BRS may represent an interesting option for patient with diffuse coronary artery disease (CAD), but data on the clinical impact of FPJ using the Absorb BRS are scant. METHODS: FPJ was defined as the implantation of >56 mm of overlapping BRS in at least one vessel. We compared outcomes of patients receiving Absorb FPJ vs. non-FPJ within the multicenter prospective RAI Registry. RESULTS: Out of 1505 consecutive patients enrolled in the RAI registry, 1384 were eligible for this analysis. Of these, 143 (10.3%) were treated with BRS FPJ. At a median follow-up of 649 days, no differences were observed between FPJ and non-FPJ groups in terms of the device-oriented composite endpoint (DoCE) (5.6% vs. 4.4%, p = 0.675) or the patient-related composite endpoint (PoCE) (20.9% vs. 15.9%, p = 0.149). Patients receiving FPJ had higher rates of target vessel repeat revascularization (TVR) (11.2% vs. 6.3%, p = 0.042). In the FPJ group, there was no cardiac death and only one (very late) stent thrombosis (ST) (0.7%). CONCLUSIONS: Mid-term outcomes of a FPJ PCI strategy in the setting of diffuse CAD did not show a significant increase in composite device- and patient-related events, with rates of cardiac death and ST comparable to non-FPJ Absorb BRS implantation. However, these findings are hypothesis generating and requiring further validation.

4 Article Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. 2018

Tarantini, Giuseppe / Masiero, Giulia / Barioli, Alberto / Paradies, Valeria / Vlachojannis, Georgios / Tellaroli, Paola / Cortese, Bernardo / di Palma, Gaetano / Varricchio, Attilio / Ielasi, Alfonso / Loi, Bruno / Steffenino, Giuseppe / Ueshima, Daisuke / Mojoli, Marco / Smits, Pieter. ·Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Maastad Ziekenhuis, Rotterdam, Netherlands. · Biostatistics, Epidemiology and Public Health Unit of Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Unità Operativa di Cardiologia, ASST Fatebenefratelli-Sacco, P.O. Fatebenefratelli, Italy. · Cardiology Division, Santa Maria della Pietà Hospital, Nola, Naples, Italy. · Cardiology Division, A.O. Bolognini, Seriate, Bergamo, Italy. · Cardiology Division, A.O. Brotzu, Cagliari, Italy. · USD Emodinamica, A.S.O. S.Croce e Carle, Cuneo, Italy. ·Catheter Cardiovasc Interv · Pubmed #29513403.

ABSTRACT: BACKGROUND: Patients with small vessel disease (SVD) are at higher risk of adverse events after PCI compared to non-SVD patients. In this subset, the use of bioresorbable vascular scaffolds (BVS) has raised particular concern. OBJECTIVE: We aimed to compare outcomes of Absorb BVS versus a 2nd-generation metallic everolimus-eluting stents (EES) in the SVD setting, by pooling patients from three large, prospective studies. METHODS: Patients with SVD (reference vessel diameter ≤2.75 mm by QCA) and treated with Absorb BVS were identified in the Italian RAI and the MAASSTAD-Absorb registries. EES controls were identified in the COMPARE II Trial. We performed a propensity-score matching using several clinical and angiographic variables. Implantation technique was not object of matching, being device-specific. RESULTS: Out of 4635 enrolled subjects, 1147 belonged to the SVD population. After matching, we obtained 337 pairs of patients. High clinical and angiographic complexity was found in both groups. Predilation and postdilation rates were significantly higher in BVS patients. No differences were found in terms of the device-oriented composite end-point at 1-year (HR = 1.08, 95%CI 0.5-2.3, P = .8) and 2-years (HR = 1.28, 95% CI: 0.68-2.43, P = .5). Notwithstanding, higher incidence of definite/probable stent thrombosis was observed in the BVS group at 1 year (HR 4.7, 95%CI 0.8-31.4, P = .08) and 2-years (HR = 8.34 95%CI 1.1-60.2, P = .04). CONCLUSION: In this propensity-matched analysis pooling SVD patients of three large prospective studies, incidence of composite device-related events was comparable between BVS and EES up to 2 years follow-up. However, higher rates of stent thrombosis were found in the BVS group.